10-Q: Synergy CHC Corp. Reports Net Income of $2 Million in Q3 2024 Despite Revenue Dip

Synergy CHC Corp. reports a net income of $2.019 million for the nine months ended September 30, 2024, despite a decrease in revenue compared to the same period in 2023.

Summary

• Synergy CHC Corp. reported a net income of $2,019,309 for the nine months ended September 30, 2024, compared to $3,747,444 for the same period in 2023.
• Revenue for the nine months ended September 30, 2024, was $24,563,036, down from $29,559,440 in the same period of 2023.
• The company experienced a decrease in Nutraceuticals revenue due to a delay in a significant shipment and the launch of a new product line in 2023.
• Gross profit for the nine months ended September 30, 2024, was $17,141,106, a decrease from $21,207,795 in the same period of 2023.
• Operating expenses decreased, with selling and marketing expenses at $9,149,303 and general and administrative expenses at $3,449,007 for the nine months ended September 30, 2024.
• EBITDA for the nine months ended September 30, 2024, was $4,793,035, compared to $6,391,660 for the same period in 2023.
• The company completed an initial public offering (IPO) in October 2024, raising approximately $8.4 million in net proceeds.
• The company restructured its debt agreements in 2024, extending terms into 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company achieved net income and completed a successful IPO, there are concerns about declining revenue, gross profit, and a working capital deficit. The company's future outlook is positive, but the current financial situation presents challenges.

Positives

• The company achieved a net income of $2,019,309 for the nine months ended September 30, 2024.
• Operating expenses decreased due to improved management of promotions and operating costs.
• The company successfully completed an IPO in October 2024, raising approximately $8.4 million in net proceeds.
• Debt agreements were restructured, extending terms into 2026.
• The company recognized $252,405 as other income from government assistance.

Negatives

• Revenue decreased to $24,563,036 for the nine months ended September 30, 2024, from $29,559,440 in the same period of 2023.
• Gross profit decreased to $17,141,106 for the nine months ended September 30, 2024, compared to $21,207,795 in the same period of 2023.
• EBITDA decreased to $4,793,035 for the nine months ended September 30, 2024, from $6,391,660 in the same period of 2023.
• The company had a working capital deficit of $6,395,684 as of September 30, 2024.
• Net cash used in operating activities was $1,377,479 for the nine months ended September 30, 2024.

Risks

• The company has a significant accumulated deficit of $44,332,980 as of September 30, 2024.
• The company has a working capital deficit of $6,395,684 as of September 30, 2024.
• The company relies on a few major customers for a significant portion of its revenue.
• The company has a high concentration of accounts payable with a few vendors.
• The company's net operating loss carryforwards may be limited or eliminated due to change of ownership rules.
• The company's ability to meet its obligations is dependent on generating enough cash from operations and other available sources.
• The company is subject to risks related to litigation and legal proceedings.

Future Outlook

The company intends to grow organically by developing new products and expanding into new markets, particularly for its FOCUSfactor ready-to-drink beverage. They also plan to grow through strategic acquisitions.

Management Comments

• Management is focused on developing current brands into new markets and by product extensions.
• Management aims to grow the Nutraceuticals and Ready To Drinks (RTDs) verticals to provide a balanced portfolio.
• Management believes that the factors mentioned alleviate doubts about the company's ability to generate enough cash to satisfy its obligations for the next twelve months.

Industry Context

The company operates in the consumer health care, beauty, and lifestyle products industry, focusing on nutraceuticals and ready-to-drink beverages. The company's performance is influenced by consumer demand, market trends, and competition within these sectors.

Comparison to Industry Standards

• The company's gross profit margin of 70% for the nine months ended September 30, 2024, is within the range of other consumer health companies, but lower than the 72% achieved in the same period of 2023.
• The company's reliance on a few major customers is a common risk in the consumer goods industry, similar to companies like Vitamin Shoppe or GNC, which also depend on key retail partners.
• The company's debt restructuring and IPO are similar to strategies used by other small to mid-sized companies in the sector to improve their financial position and fund growth, such as those seen by companies like Celsius Holdings or Nutraceutical International Corp.
• The company's focus on online and retail channels is consistent with the omnichannel approach adopted by many consumer health brands, such as those used by companies like iHerb or Amazon's private label brands.

Corporate Governance

Legal Proceedings

• The company settled a lawsuit with a contract manufacturer in December 2023, resulting in a net gain of $2,235,986 and a loan payable of $5,450,000.
• The company settled a breach of contract claim with L.O.D.C. Group in April 2024, which was accounted for as a charge to operations for the year ended December 31, 2023.

Related Party Transactions

• The company has significant related party transactions, including loans and consulting fees with entities controlled by the CEO and Knight Therapeutics.
• The company advanced $396,683 in prepaid consulting fees to a related party, applying $328,003 of that advance to a short term loan.
• The company was advanced $3,020,000 and $514,500 Canadian Dollars in the form of a short term note from a related party.
• The company has various loan agreements with Knight Therapeutics, including a consolidated loan with a maturity date of March 31, 2026.
• The company has distribution agreements with Knight Therapeutics for FOCUSFactor and Hand MD in Canada, with fees based on gross sales.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance, including the decrease in revenue and gross profit, but also by the successful IPO.
• Employees may be affected by the company's cost management efforts and strategic initiatives.
• Customers may be impacted by the company's product development and market expansion efforts.
• Suppliers may be affected by the company's purchasing decisions and payment terms.
• Creditors are impacted by the company's debt restructuring and repayment obligations.

Next Steps

• The company intends to organically grow its current product lines by developing and launching new products and expanding into new markets.
• The company is working on increased distribution for its recently launched ready-to-drink beverage.
• The company intends to grow further through additional strategic acquisitions and continues to evaluate opportunities.

Key Dates

Keywords

Synergy CHC Corp, financial results, net income, revenue, EBITDA, IPO, debt restructuring, consumer health care, FOCUSfactor, Flat Tummy, Nutraceuticals